Arrowstreet Capital Limited Partnership Has $33.88 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Arrowstreet Capital Limited Partnership decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 53.2% in the 4th quarter, HoldingsChannel reports. The firm owned 101,961 shares of the company’s stock after selling 115,691 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Medpace were worth $33,875,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. R Squared Ltd bought a new position in shares of Medpace in the fourth quarter valued at about $30,000. SBI Securities Co. Ltd. bought a new stake in Medpace during the 4th quarter worth about $31,000. Jones Financial Companies Lllp increased its position in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after acquiring an additional 110 shares in the last quarter. Lindbrook Capital LLC raised its stake in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares during the last quarter. Finally, Assetmark Inc. grew its stake in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Up 4.5 %

Medpace stock opened at $311.23 on Thursday. The firm has a market capitalization of $9.48 billion, a P/E ratio of 24.64, a PEG ratio of 3.81 and a beta of 1.45. The business has a 50-day moving average of $333.58 and a 200-day moving average of $338.33. Medpace Holdings, Inc. has a 1 year low of $289.01 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on MEDP shares. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Leerink Partners initiated coverage on Medpace in a research note on Monday, March 24th. They set a “market perform” rating and a $330.00 price target on the stock. Finally, Robert W. Baird lifted their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.